Optimizing Complex Pulmonary Arterial Hypertension Care: Enhancing Adherence and Outcomes

For this analysis, outcomes were compared between individuals who had pulmonary arterial hypertension (PAH) and healthy controls by using Fitbit-derived data over 12 weeks and then at a 1-year follow-up.

The findings from this single-center retrospective study compare outcomes between 2 groups of patients living with connective tissue disease–associated pulmonary arterial hypertension (CTD-PAH) stratified by their Heart Failure Association–preserved ejection fraction (HFA-PEFF) algorithm score.

Three decades of data from the Global Burden of Disease Study were analyzed for trends in global, regional, and national burdens in pulmonary arterial hypertension (PAH).

Patients taking sotatercept had a 76% relative risk reduction in morbidity and mortality events compared with patients taking placebo.

Pulmonary hypertension is a common consequence of interstitial lung disease (PH-ILD), with the highest rate seen among individuals who have idiopathic pulmonary fibrosis. Overall, most cases of PH in the setting of ILD are mild.

New topline data from the Launch-HTN (NCT06153693) and Advance-HTN (NCT06153693) clinical trials show these investigations met their primary end points os statistically significant reductions in systolic blood pressure.